Galili N, Devens B, Naor D, Becker S, Klein E
Eur J Immunol. 1978 Jan;8(1):17-22. doi: 10.1002/eji.1830080105.
This report describes model systems which show low primary in vitro syngeneic cytotoxic responses to a Moloney-induced YAC tumor (syngeneic in A mice) and a Rauscher-induced RBL5 tumor (syngeneic in C57BL/6 mice) and examines different approaches to overcome these defects. Two major findings were obtained: (a) spleen cells from A mice, injected with tumor cells from an in vitro tumor line YAC-1, derived from YACL, could generate a significant syngeneic cytotoxic response. In contrast, spleen cells from A mice injected with tumor cells from the in vivo tumor line failed to generate a syngeneic cytotoxic response. Thus, tumor cells from the in vitro line were more immunogeneic that those from the in vivo line. (b) Spleen cells from A mice which were injected with the cross-reactive allogeneic tumor RBL5, could generate significant cytotoxic responses to the syngeneic tumors YAC and YAC-1. Similarly, spleen cells from C57BL/6 mice injected with the cross-reactive allogeneic tumor YAC-1, could generate a significant cytotoxic response to the syngeneic tumor RBL5. Thus, cross-reactive allogeneic tumors could stimulate syngeneic cytotoxicity. The theoretical and the practical implications of these studies are discussed.
本报告描述了一些模型系统,这些系统对莫洛尼氏病毒诱导的YAC肿瘤(在A小鼠中为同基因)和劳舍尔氏病毒诱导的RBL5肿瘤(在C57BL/6小鼠中为同基因)显示出较低的原发性体外同基因细胞毒性反应,并研究了克服这些缺陷的不同方法。获得了两个主要发现:(a)将来自体外肿瘤细胞系YAC-1(源自YACL)的肿瘤细胞注射到A小鼠的脾细胞中,可产生显著的同基因细胞毒性反应。相比之下,将来自体内肿瘤细胞系的肿瘤细胞注射到A小鼠的脾细胞中,则无法产生同基因细胞毒性反应。因此,体外细胞系的肿瘤细胞比体内细胞系的肿瘤细胞具有更强的免疫原性。(b)将交叉反应性异基因肿瘤RBL5注射到A小鼠的脾细胞中,可对同基因肿瘤YAC和YAC-1产生显著的细胞毒性反应。同样,将交叉反应性异基因肿瘤YAC-1注射到C57BL/6小鼠的脾细胞中,可对同基因肿瘤RBL5产生显著的细胞毒性反应。因此,交叉反应性异基因肿瘤可刺激同基因细胞毒性。讨论了这些研究的理论和实际意义。